Skip to search formSkip to main contentSkip to account menu

MLN 8237

Known as: Aurora A Kinase Inhibitor MLN8237, MLN-8237, MLN8237 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AzepinesPyrimidines

Narrower (1)

alisertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
BACKGROUND Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA… 
Highly Cited
2016
Highly Cited
2016
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Highly Cited
2015
Highly Cited
2015
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis… 
Highly Cited
2015
Highly Cited
2015
Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
BACKGROUND Aurora Kinase A (AURKA) encodes a protein that regulates the formation and stability of the mitotic spindle and is… 
Highly Cited
2013
Highly Cited
2013
Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
BACKGROUND & AIMS Chronic inflammation contributes to the pathogenesis of gastric tumorigenesis. The aurora kinase A (AURKA) gene… 
Highly Cited
2012
Highly Cited
2012
Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
Highly Cited
2012
Highly Cited
2012
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
Purpose: This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral… 
Highly Cited
2012
Highly Cited
2012
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Purpose: MLN8237, a selective small-molecule inhibitor of Aurora kinase A, has activity in a broad range of preclinical pediatric… 
Highly Cited
2011
Highly Cited
2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
2011
2011
Aurora A kinase activity is required for localization of TACC3/ch-TOG/clathrin inter-microtubule bridges.
Accurate chromosome segregation during mitosis is achieved by the kinetochore fibers (K-fibers) of the spindle apparatus. These… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)